Dow Jones industrial average index futures fell 0.02%, Standard & Poor's 500 index futures were off 0.05% and Nasdaq index futures declined 0.04%
Asian stock markets steadied Tuesday after a sharp sell-off the day before. Japan's Nikkei 225 stock average was up 0.6% at 15,210.32 and Hong Kong's Hang Seng added 0.1% to 22,296.00. China's Shanghai Composite fell 0.2% to 1,996.68.
Markets across Europe were mixed, with London's FTSE 100 down 0.19% and Germany's DAX up 0.28%.
Benchmark U.S. crude for April delivery was up 1 cent at $101.11 a barrel in electronic trading on the New York Mercantile Exchange. The contract fell $1.46 to close at $101.12 a barrel Monday.
On Wall Street Monday, the S&P 500 index edged down 0.87 of a point to close at 1,877.17. The Dow lost 34.04 points, or 0.2%, to 16,418.68. The Nasdaq composite fell 1.77 points, or less than 0.1%, to 4,334.45.
Hot Supermarket Stocks To Buy Right Now: Fuwei Films(Holdings)
Fuwei Films (Holdings) Co., Ltd., together with its subsidiaries, engages in the development, manufacture, distribution, and export of plastic film using the biaxially-oriented stretch technique in China. The company offers its biaxially oriented polyethylene terephthalate (BOPET) film under the ?Fuwei Films? brand name primarily for use in flexible packaging, printing, laminating, and aluminum-plating applications, as well as in electrical and electronic uses. Its products include printing base film used in printing and lamination applications; stamping foil base film and transfer base films used for the packaging of luxury items, such as cigarettes and alcohol; metallization film or aluminum plating base film used for vacuum aluminum plating for flexible plastic lamination; high-gloss film used for aesthetically enhanced packaging purposes; and heat-sealable film used for construction, printing, and heat sealable bags making. The company?s products also comprise laser holographic base film used as anti-counterfeit film for food, medicine, cosmetics, cigarettes, and alcohol packaging; dry film used in circuit boards production, and for nameplate and crafts etching; and heat shrinkage film used for special-shaped packaging for alcohol, cans, mineral water, and cleaning products. It exports its products to packaging customers and distributors primarily in Europe, Asia, and North America. The company was founded in 2003 and is headquartered in Weifang, China. As of May 1, 2011, Fuwei Films (Holdings) Co., Ltd. operates as a subsidiary of Weifang State-owned Assets Operation Administration Company.
Advisors' Opinion:- [By Adam Haigh]
Among stocks that fell, Yue Yuen Industrial (Holdings) Ltd. (551), a supplier of shoes to Nike Inc. and Adidas AG, sank 12 percent to HK$23.80. The company said its first-quarter results showed a ��ignificant downturn��compared with a year earlier and this could adversely affect interim performance.
Top 5 Asian Companies For 2014: Paradise Inc (PARF)
Paradise, Inc., incorporated in September, 1961, conducts operations through two business segments: Candied Fruit and Molded Plastics. The Candied Fruit segment is engaged in the production of candied fruit, a basic fruitcake ingredient, sold to manufacturing bakers, institutional users, and retailers for use in home baking. Based on market conditions, it is also engaged in the processing of frozen strawberry products for sale to commercial and institutional users, such as preservers, dairies and drink manufacturers. The Molded Plastics segment is engaged in the production of plastic containers for the Company�� products and other molded plastics for sale to unaffiliated customers.
During the year ended December 31, 2011, in terms of candied fruit sales, approximately 20% were shipped to manufacturing bakers and other institutional users, with the balance being sold through supermarkets and other retail outlets for ultimate use in the home. Sales to retail outlets are usually generated through registered food brokers operating in exclusively franchised territories.
The Company�� trademarks Paradise, Dixie, Mor-Fruit and Sun-Ripe are registered with the appropriate Federal and State authorities for use on the Company�� candied fruit. During 2011, the Company derived approximately 15% of its consolidated net sales from Wal-Mart Stores, Inc.
Advisors' Opinion:- [By Geoff Gannon]
What is the advantage of being a huge company? There are some. For one, we know the business is ��or was ��growable. A lot of small companies stay small because their circle of competence is small. Paradise (PARF) is an over the counter stock. It has a market cap of $10 million. And it dominates the candied fruit market in the U.S. Why isn�� the company bigger?
Top 5 Asian Companies For 2014: Paulson Capital Corp.(PLCC)
Paulson Capital Corp., through its subsidiary, Paulson Investment Company, Inc., operates as a brokerage company principally in the United States. It engages in securities brokerage activities, which include acting as agent for purchase and sale of common and preferred stocks, options, warrants, and debt securities traded on securities exchanges or in the over-the-counter market. The company?s corporate finance activities comprise underwriting initial and follow-on public offerings, private investments in public equity, and private placements for smaller companies; securities trading and market making activities consist of executing trades in equity securities, corporate debt securities, and municipal bonds; and market making activities are conducted with dealers in the wholesale market and its customers. Its investment activities include holding securities for investment, which primarily include securities purchased for investment and underwriter warrants. As of December 31, 2010, the company operated 39 branch offices in California, Colorado, Connecticut, Florida, Georgia, New Jersey, New York, Oregon, Utah, and Washington. Paulson Capital Corp. was founded in 1969 and is based in Portland, Oregon.
Advisors' Opinion:- [By CRWE]
Paulson Capital Corp. (Nasdaq:PLCC), parent company of Paulson Investment Company, Inc., reported a net income of $1,412,294 (or $0.24 per share) for the three months ended March 31, 2012 versus a net loss of $381,210 (or ($0.07) per share) for the like period in 2011.
Top 5 Asian Companies For 2014: Regeneron Pharmaceuticals Inc.(REGN)
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The company?s commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical development stage consist of VEGF Trap-Eye, an aflibercept ophthalmic solution developed using intraocular delivery for the treatment of serious eye diseases; ARCALYST for the prevention of gout flares in patients initiating uric acid-lowering treatment; and Aflibercept (VEGF Trap), which is developed in oncology. The company?s earlier stage clinical programs include various human antibodies, such as REGN727 for low-density lipoprotein cholesterol reduction, REGN88 for rheumatoid arthritis and ankylosing spondylitis; REGN668 for atopic dermatitis and asthma; REGN421 and REGN910 for oncology; REGN475 for the treatment of pain; and REGN728 and REGN846. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with sanofi-aventis Group to discover, develop, and commercialize human monoclonal antibodies; and Bayer HealthCare LLC to develop and commercialize VEGF Trap. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is based in Tarrytown, New York.
Advisors' Opinion:- [By Maxx Chatsko]
In the following video, Fool contributor Maxx Chatsko reviews the biggest catalysts for�Regeneron's� (NASDAQ: REGN ) recent climb and near-rendezvous with $300 per share. The emerging biotech powerhouse has treated investors well in recent years -- returning more than 1,200% since 2008. While the company no doubt has a promising future, investors may be curious if things are getting too hot too fast. Did investors overreact to prior developments this year? Are shares priced for perfection? Or is $300 per share a benchmark that is actually within reach? The key lies in the pipeline.
- [By Lauren Pollock]
A treatment for a diabetic eye condition improved vision during a Phase 3 trial, Regeneron Pharmaceuticals Inc.(REGN) and Bayer HealthCare said Monday.
- [By Ben Levisohn]
Investors are eying big gains in Regeneron Pharmaceuticals (REGN) following its earnings release today, which featured good news on the biotech company’s blockbuster-to-be, Eylea.
Getty ImagesReuters has the details on Regeneron’s results:
Regeneron Pharmaceuticals Inc forecast U.S. sales of eye drug Eylea to reach $1.7-$1.8 billion in 2014 as it expects the drug to win approval for newer uses, sending its shares up 3 percent before the opening bell.
Regeneron, whose stock has been propelled by the success of Eylea, said U.S. sales of the sight-saving drug rose 46 percent to $402 million in the fourth quarter. The drug’s international sales touched $184 million in the quarter…
The company’s net income fell to $97 million, or 86 cents per share, in the quarter ended December 31, from $470 million, or $4.08 per share, a year earlier. The year-ago quarter included a non-cash tax benefit of $336 million.
Analysts had expected a profit of 98 cents per share, according to Thomson Reuters I/B/E/S.
RBC Capital Market’s Adnan Butt and team note that Eylea sales could be better than management forecasts:
The trend shows growth over 4Q run-rate and is deemed a positive as management is typically viewed as conservative when it comes to guidance. Questions on the call will focus on what is included, i.e., whether it includes DME or not which is not yet approved. We like [Regeneron] for the blockbuster potential of Eylea and the deep pipeline and are buyers, especially on any pullbacks. It is one of our top ideas for 2014.
Brean Capital’s Jonathan Aschoff and Yi Cheng raise their target price on Regeneron to $380 from $367. They explain why:
4Q13, U.S. Eylea sales were hurt by the holiday season but helped by an increase in inventory held by distributors to over two weeks, which should negatively affect sequential Eylea sales in 1Q14. In 4Q13, Eylea had 50% of the U.S
- [By Ben Levisohn]
Biotech stocks aren’t falling much today, however. The iShares Nasdaq Biotechnology ETF has dropped 0.5% to $254.31, while Biogen Idec (BIIB) is off 0.3% to $335.85 and Amgen (AMGN) and Regeneron Pharmaceuticals (REGN) are little changes at $122.25 and $304.41, respectively.
No comments:
Post a Comment